Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 | P35367 | 17/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 15/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 8/20 | 0.57 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.56 |
| ▸ | HTR3A | P46098 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3769163 | 0.98 | HRH1 (0.58) | HRH1CYP2D6KCNH2CHRM1HTR3A | |
| SCHEMBL15567158 | 0.83 | HRH1 (0.64) | HRH1CYP2D6KCNH2CHRM1HTR3A | |
| SCHEMBL10429053 | 0.80 | HRH1 (0.74) | HRH1CYP2D6KCNH2CHRM1HTR3A | |
| SCHEMBL15568031 | 0.80 | HTR3A (0.66) | HRH1CYP2D6KCNH2CHRM1HTR3A | |
| SCHEMBL27317913 | 0.77 | HRH1 (0.69) | HRH1CYP2D6KCNH2CHRM1HTR3A | |
| SCHEMBL18292404 | 0.77 | HRH1 (0.65) | HRH1CYP2D6KCNH2CHRM1HTR3A | |
| SCHEMBL5229655 | 0.76 | HRH1 (0.73) | HRH1CYP2D6KCNH2CHRM1HTR3A | |
| SCHEMBL13004959 | 0.76 | MEN1 (0.62) | — | |
| SCHEMBL15568131 | 0.75 | HRH1 (0.61) | HRH1CYP2D6KCNH2CHRM1HTR3A | |
| SCHEMBL15568527 | 0.75 | HRH1 (0.66) | HRH1CYP2D6KCNH2CHRM1HTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7851474-B2 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION (US) | 2010-12-14 | — | — | US | disclosed |
| US-7851474-B2 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION (US) | 2010-12-14 | — | — | US | disclosed |
| US-7851474-B2 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION (US) | 2010-12-14 | — | — | US | disclosed |
| US-20070049571-A1 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION | 2007-03-01 | — | — | US | disclosed |
| US-20070049571-A1 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION | 2007-03-01 | — | — | US | disclosed |
| US-20070049571-A1 | Dipiperazinyl ketones and related analogues | NEUROGEN CORPORATION | 2007-03-01 | — | — | US | disclosed |
| WO-2007016496-A2 | DIPIPERAZINYL KETONES AND RELATED ANALOGUES | NEUROGEN CORPORATION (US) | 2007-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049571-A1 | Dipiperazinyl ketones and related analogues | HRH4, HRH3, HRH1 | HRH1 3/4885CYP2D6 1492/4885KCNH2 130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.